Highlights of This Issue 553

REVIEW

555 | New Paradigms in Microtubule-Mediated Endocrine Signaling in Prostate Cancer
Sucharita J. Mistry and William K. Oh

CHEMICAL THERAPEUTICS

567 | A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo
Hidetoshi Kuruma, Hiroaki Matsumoto, Masaki Shioti, Jennifer Bishop, Francois Lamoureux, Christian Thomas, David Briere, Gerrit Los, Martin Gleave, Andrea Fanjul, and Amina Zoubeidi

577 | Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
Warren Fiskus, Srdan Verstovsek, Taghi Manshouri, Jacqueline E. Smith, Karissa Peth, Sunil Abhyankar, Joseph McGuirk, and Kapil N. Bhalla

589 | Afinatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model
Takashi Ninomiya, Nagio Takigawa, Eiki Ichihara, Nobuaki Ochi, Toshi Murakami, Yoshihiro Honda, Toshi Kudo, Dai-suKe Minami, Kenichihiro Kudo, Mitsune Tanimoto, and Katsuyuki Kiura

598 | Tandutinib Inhibits the Akt/mTOR Signaling Pathway to Inhibit Colon Cancer Growth
Sivapriya Ponnurangam, David Standing, Parthasarathy Rangarajan, and Dharinalaingam Subramaniam

563 | Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
Warren Fiskus, Srdan Verstovsek, Taghi Manshouri, Jacqueline E. Smith, Karissa Peth, Sunil Abhyankar, Joseph McGuirk, and Kapil N. Bhalla

577

589

598

563

SMALL MOLECULE THERAPEUTICS

675 | Activity of a Py-Im Polyamide Targeted to the Estrogen Response Element
Nicholas G. Nickols, Jerzy O. Szablowski, Amanda E. Hargrove, Benjamin C. Li, Jevgenij A. Raskatov, and Peter B. Dervan
**LARGE MOLECULE THERAPEUTICS**

685  
**A Novel Monoclonal Antibody to Secreted Frizzled-Related Protein 2 Inhibits Tumor Growth**  
Emily Fontenot, Emma Rossi, Russell Mumper, Stephanie Snyder, Sharareh Siakampour-Reihani, Ping Ma, Eleanor Hilliard, Bradley Bone, David Ketelsen, Charlene Santos, Cam Patterson, and Nancy Klauber-DeMore

759  
**Targeting FoxM1 Effectively Retards p53-Null Lymphoma and Sarcoma**  
Zebin Wang, Yu Zheng, Hyun Jung Park, Jing Li, Janai R. Carr, Yi-yu Chen, Megan M. Kiefer, Dragana Kopanja, Srilata Bagchi, Angela L. Tyner, and Pradip Raychaudhuri

**CANCER THERAPEUTICS INSIGHTS**

696  
**ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non–Small Cell Lung Cancer Expressing EML4-ALK**  
Yunguang Sun, Kamila A. Nowak, Nicholas G. Zaorsky, Chia-Lin Winchester, Kunal Dalal, Nicholas J. Giacalone, Ningbo Liu, Maria Werner-Wasik, Mariusz A. Wasik, Adam P. Dicker, and Bo Lu

777  
**Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells**  
Xingnan Zheng, Kan He, Lin Zhang, and Jian Yu

787  
**Impact of Tumor Vascularity on Responsiveness to Antiangiogenesis in a Prostate Cancer Stem Cell-Derived Tumor Model**  
Kexiong Zhang and David J. Waxman

809  
**A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O6-Methylguanine-DNA Methyltransferase Promoter**  
Daniel Hochhauser, Rob Glynn-Jones, Vanessa Potter, Cristina Grávalos, Thomas J. Doyle, Kumudu Pathiraja, Qing Zhang, Ling Zhang, and Edward A. Sausville

**TOOLS & TECHNOLOGIES**

819  
**[18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941**  
Christopher Cawthorne, Natalie Burrows, Roben G. Gieling, Christopher J. Morrow, Duncan Forster, Jamil Gregory, Marc Radigois, Alison Smigova, Muhammad Babur, Kathryn Simpson, Cassandra Hodkinson, Gavin Brown, Adam McMahon, Caroline Dive, Duncan Hiscock, Ian Wilson, and Kaye J. Williams
ABOUT THE COVER

Mitochondria is the powerhouse of cells (structure, green), supplying the majority of ATP that is essential for cell survival. However, cancer cells present a distinct glycolytic metabolism profile (Warburg effect), which is linked to the malignant transformation process. The emerging anti-VEGF therapy fights cancers by starving the energy supplement, but it was found to enhance the Warburg effect and induce even more aggressive phenotypes. Cancer cells with acquired resistance to anti-VEGF therapy display impaired mitochondria structure and hyperactive glycolytic metabolism, which render them vulnerable to glycolysis blockade therapy. For details, see article by Xu and colleagues on page 717.
Molecular Cancer Therapeutics

12 (5)


Updated version  Access the most recent version of this article at: http://mct.aacrjournals.org/content/12/5

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.